【摘要】 心血管并发症是2型糖尿病(T2DM)患者的主要并发症,也是其首要的死亡原因。因此在T2DM的治疗中,除了控制血糖外,预防患者的心血管并发症也尤为重要。大量临床和基础研究结果证实,钠-葡萄糖协同转运蛋白2抑制剂在降低血糖的同时,可减少心血管危险因素和心血管事件的发生。其中,卡格列净作为首个获得美国FDA批准的钠-葡萄糖协同转运蛋白2抑制剂类药物,其对T2DM患者的心血管保护作用已被研究证实。现主要针对卡格列净对T2DM患者心血管保护作用和可能的作用机制做一简要综述。更多还原

【Abstract】 Cardiovascular complications are a major complication of patients with type 2 diabetes( T2 DM) and are the leading cause of death. In the treatment of T2 DM, in addition to controlling blood glucose, it is especially important to prevent cardiovascular complications in patients. A large number of clinical and basic studies have confirmed that sodium-glucose cotransporter 2 inhibitors( SGLT-2 inhibitors) can reduce cardiovascular risk and reduce cardiovascular events while reducing blood glucose. As the first FDA-approved SGLT-2 inhibitor,canagliflozin has been confirmed that it can protect the cardiovascular system in patients with T2 DM. This article is mainly aimed at a brief review of the cardiovascular protection and possible mechanisms of canagliflozin in patients with T2 DM.更多还原